Bioavailability and plasma concentration of omeprazole in healthy bangladeshi population after ingestion.
This cross-sectional observational study was conducted in the department of Gastroenterology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. Plasma concentration of omeprazole was assayed in the quality control laboratory of Novartis (Bangladesh) Limited, Tongi, Gazipur, Bangladesh. The study was conducted from January 2006 to April 2007 and was designed to find out the bioavailability of omeprazole in capsule form in healthy Bangladeshi population and to compare this with that of the other population in the world. Twelve healthy volunteers were included in this study. The subjects were divided into two groups; six of them were randomly selected in each. One group received 40mg omeprazole intact capsule of one trade and other group received 40mg omeprazole intact capsule of another trade once daily for consecutive 8 days at 8.00 hours on each day. On the first and eight days of dosing, 10ml of blood sample was collected from each subject at 0.0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0 and 6.0 hours after dosing. Blood samples were centrifuged at 2500rpm for 15 minutes and plasma was stored at 20°C. Omeprazole concentration in plasma was determined using a reverse phase high performance liquid chromatography (HPLC). From the concentration, the area under the curve (AUC) of omeprazole was determined for each subject by the trapezoidal rule. From the result it was observed that the plasma concentration of omeprazole was increased up to 6 hours in both trade-A and trade-B in day 1 and 8. Thus the AUC of omeprazole was also increased. But most of the studies in western population showed that the maximum plasma concentration was within 0.5 to 2.0hours indicating a difference from that of western studies. In this study all the subjects exhibited increased plasma concentration and AUC which may be due to genetic variation of omeprazole metabolism as an Asian which may be due to slow or "Poor metabolizers" (PMs), of the study population, who are deficient in CYP2C19. It is revealed that the plasma concentration and AUCs of both the products after single and repeated doses of omeprazole capsule were higher in comparison to other studies in western population.